Skip to content

Effect of anti-aging tablets on improving cognitive function of Mild and moderate Alzheimer's disease

Effect of anti-aging tablets on improving cognitive function of Mild and moderate Alzheimer's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005443
Enrollment
Unknown
Registered
2021-12-24
Start date
2021-12-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Donepezil + anti-aging tablets (experimental group) :Donepezil + anti-aging tablets

Sponsors

Hangzhou 7th People's Hospital / Mental Health Center affiliated to Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Meet the probable diagnostic criteria of NINCDS-ADRDA for AD dementia, and the course of disease is =6 months. ? Simplified Mental State Assessment Scale (MMSE) (11=MMSE score =26, 11=MMSE score =24 for primary education); ? Age =65 years old, =85 years old, male and female; ? Have a primary school education or above and have the ability to complete the test required by the program. ? Receive a comprehensive neuropsychological assessment; Hachinski ischemia scale =4 points; Hamilton Depression Scale (HAMD) =10; ? Patients with deficiency of qi and Yin in TCM syndrome differentiation; There should be stable accompanying personnel, or at least 4 days a week, 2 hours a day contact with the accompanying personnel. The attendant should assist the patient throughout the trial;No obvious positive signs in neurological examination; ? The patients and/or their family members sign the informed consent and agree to participate in all visits, examinations and treatment in accordance with the requirements of the study protocol.

Exclusion criteria

Exclusion criteria: ? Exclude dementia caused by other diseases, such as vascular dementia, frontotemporal dementia, lewy body dementia, etc.; Thyroid disease, parathyroid disease, alcoholism, drug intoxication, brain tumor, normal pressure hydrocephalus, etc. ? Pseudodementia caused by depression (HAMD=17); ? Routine laboratory studies, including vitamin B12 levels, folic acid levels and thyroid hormone levels; Quantitative HIV antibody and serological examination of syphilis were performed to exclude dementia patients caused by other factors. ? patients with a history of mental illness (such as schizophrenia) or influence collaborators; ? Exclude epilepsy, alcohol or psychotropic drug abuse history; ? Acute stage of cardiovascular, lung, liver, kidney, hematopoietic system and other major body diseases; ? There are contraindications to Mr Examination; ? severe abnormalities of hearing and vision; ? TCM syndrome differentiation: non-qi and Yin deficiency syndrome.

Design outcomes

Primary

MeasureTime frame
community structure and composition of intestinal flora;Head-MRI;Scale to assess;

Countries

china

Contacts

Public ContactZhang Xueping
504499532@qq.com13868081273

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026